Correspondingly, disrupting MHC1/LILRB1 has shown both preclinical and clinical therapeutic activity against several types of cancers, behaving like the established immune checkpoints such as PD-1/PD-L1 and CD47/Sirpα which have been extensively reviewed elsewhere (15, 16). Here, LILRB1 is linked to cancer.